Working to improve diagnosis and treatment for patients with diabetic retinopathy Nearly 90 percent of people living with diabetes will eventually go blind. Diabetic retinopathy is caused by diseased vessels in the retina leaking blood components or hemorrhaging. The affects increasingly distort vision because of scarring of the retina and, in its most advanced stage, leads to blindness. The damage is irreparable increasing the importance of early diagnosis. The current diagnostic procedure is Fluorescein Angiography, a standard eye test performed by an ophthalmologist, who uses a special dye and camera to look at blood flow in the retina. The ophthalmologist visually reads the images and provides a diagnosis based on qualitative analysis. The founder of Emagix, Dr. Alon Friedman together with his team, developed software that reduces the testing time while enhancing the current images and providing results that enable a quantitative analysis. The software uses an algorithm that processes multiple images to produce a single, finer grain image, which makes previously imperceptible leaks from tiny capillaries as noticeable as much larger leaks from bigger vessels. In short, this innovation promises to reduce the subjectivity involved in reading the test results dramatically. Additionally, this process will enable much more precise and objective analysis of treatment effectiveness. Dr. Friedman moved his research to Dalhousie University from Ben-Gurion University in Israel in 2014 after being attracted to the university and the province of Nova Scotia because of its business community and provincial support from organizations such as ACOA, Innovacorp and BioNova. The gain was also a big one for Dalhousie, Dr. Friedman is one of the top researchers globally in his field and has received over $9 million in research funding over the past decade. The software can be integrated into existing equipment and will provide ophthalmologists with much more valuable data that promises to significantly improve diagnosis and treatment efficacy not only for patients at risk of diabetic retinopathy but also patients with Alzheimer’s Disease, Stroke, brain injuries and other diseases that are caused by leakage from blood vessels.]]>
BIONOVA CONTACT
#46 1344 Summer Street
Halifax, Nova Scotia
Canada B3H 0A8
Phone: 902-421-5705
Fax: 902-421-2733
Email: [email protected]
Halifax, Nova Scotia
Canada B3H 0A8
Phone: 902-421-5705
Fax: 902-421-2733
Email: [email protected]

Recent Posts
- NEWS RELEASE: Doris Grant appointed Vice President Business Development and Strategy at BioNova
- MARS VR Lab
- Workinsights
- NEWS RELEASE: BioNova Announces MycoFutures North Atlantic as the Winner of the Eleventh Annual BioInnovation Challenge (BIC) at BioPort 2021
- NEWS RELEASE: BioNova’s BioPort 2021 Conference for Health and Life Sciences Kicks-Off Today
Business Wire National BioTech News
- ZYUS Announces Concurrent Private Placement of Subscription Receipts in Connection With Previously Announced RTO
- AmbioPharm To Utilize YMC Twin-Column Chromatography in Large Scale Peptide Production
- IMV Inc. Announces Changes to Its Board of Directors
- European Patent Office to Grant BioKey’s Patent Application for Foundational HYFT® Technology
- Miravo Healthcare Ranks on The Globe and Mail’s Fourth-Annual Women Lead Here Benchmark of Executive Gender Diversity
- ImmunoPrecise Presents Novel T-Cell Engaging Bispecific Antibodies Addressing a Unique Oncological Target, Tropomyosin Receptor Kinase B, Associated with Poor Prognosis and Survival Rates
- dentalcorp Reports Fourth Quarter and Full Year Fiscal 2022 Results
- Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application
- Internship Program Empowers Canada’s Next Generation of Bio-Economy Workers
- BIOTECanada Welcomes Government of Canada’s Strategy on Improving Access to Care for Patients with Rare Diseases
RECENT NEWS
- NEWS RELEASE: Doris Grant appointed Vice President Business Development and Strategy at BioNova February 9, 2023
- MARS VR Lab January 25, 2022
- Workinsights January 25, 2022
- NEWS RELEASE: BioNova Announces MycoFutures North Atlantic as the Winner of the Eleventh Annual BioInnovation Challenge (BIC) at BioPort 2021 November 8, 2021
- NEWS RELEASE: BioNova’s BioPort 2021 Conference for Health and Life Sciences Kicks-Off Today November 2, 2021
- NEWS RELEASE: BioNova Selects Eight Semi-Finalists to Participate in the 11th Annual BioInnovation Challenge August 24, 2021
RECENT TWEETS
Mark your calendars! We will be hosting a panel discussion on the value of the upcoming @IAmBiotech International Conference. We'll be covering the value and opportunities for startups, established companies, & health authorities.
Stay tuned for more details in the coming weeks! https://t.co/Ure8lfdR9C
Stay tuned for more details in the coming weeks! https://t.co/Ure8lfdR9C

What a fantastic morning! Today we hosted a Meet & Greet with BioNova's newest team member, Doris Grant, who officially joined us this week.
Thank you everyone for taking the time to join us in welcoming Doris! https://t.co/mPcmgJ8Cp6
Thank you everyone for taking the time to join us in welcoming Doris! https://t.co/mPcmgJ8Cp6
